Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Up 67.8% in May

Plus Therapeutics, Inc. (NASDAQ:PSTV) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 3,490,000 shares, a growth of 67.8% from the April 30th total of 2,080,000 shares. Currently, 22.5% of the company’s shares are short sold. Based on an average trading volume of 16,940,000 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

PSTV has been the topic of several research analyst reports. D. Boral Capital reissued a “hold” rating on shares of Plus Therapeutics in a research note on Monday, May 5th. Ascendiant Capital Markets boosted their target price on shares of Plus Therapeutics from $19.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, April 21st. HC Wainwright reduced their price target on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating for the company in a research report on Friday, March 28th. Finally, D Boral Capital lowered shares of Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, May 5th.

Institutional Investors Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. Virtu Financial LLC purchased a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the first quarter, according to its most recent disclosure with the SEC. The firm purchased 40,030 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned approximately 0.24% of Plus Therapeutics at the end of the most recent quarter. 3.28% of the stock is currently owned by institutional investors and hedge funds.

Plus Therapeutics Stock Up 58.9%

Shares of NASDAQ PSTV traded up $0.17 during midday trading on Monday, reaching $0.46. 67,381,555 shares of the company’s stock traded hands, compared to its average volume of 4,727,215. The company has a market cap of $7.75 million, a price-to-earnings ratio of -0.18 and a beta of 0.88. The stock’s 50 day simple moving average is $0.68 and its 200-day simple moving average is $0.98. Plus Therapeutics has a one year low of $0.24 and a one year high of $2.67.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings data on Friday, May 30th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.39). The firm had revenue of $1.06 million during the quarter, compared to analysts’ expectations of $1.11 million. Equities analysts predict that Plus Therapeutics will post -2.3 EPS for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.